Our recent webcast on the New Surprise Billing and Financial Transparency Legislation prompted many questions. Watch the Q&A and download the transcript!Continue reading
We recently hosted a webcast on the New Surprise Billing and Financial Transparency Legislation. Download the slides and watch the recording!Continue reading
What providers, payors, and patients need to know about the No Surprises Act and how CMT’s new product, seeQer, can help providers, labs, payors, and patients alike.Continue reading
According to a recent survey conducted by the American Medical Association, 94% of physicians reported care delays due to waiting for health insurers to authorize vital care during the COVID-19 pandemic. Get the details here.Continue reading
Under the AIM Specialty Health program, laboratories are not permitted to submit prior authorization for a test on behalf of a physician. CMT Solutions can help with these new requirements!Continue reading
Coronavirus Disease or COVID-19 is the name for the respiratory syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
CMT Solutions continues to closely monitor the situation. Our priority is the health and safety of our employees, patients, physicians, laboratories, and the communities we serve. We want to help reduce the risk of spread and exposure while at the same time providing our high quality of services under these challenging conditions.
We are making sure that we are staffed and operational to help our partners and patients with all their laboratory diagnostic testing needs.
Our company has multiple physical CMT locations that our employees can work out of, as well as remote employees, giving flexibility and optimal sourcing to continue to perform our necessary workflow. CMT currently has 5 operations employees that are dedicated remote staff.
The team here is currently preparing to have all of our operations employees equipped with the ability to work remotely, if it is necessary for them to do that. Additionally, we are communicating the requirements of working remotely, given the complexity and security of the nature of our work.
For those who have been directly affected by the COVID-19 you are in our thoughts. Now is a time to come together and help and support one another as we find our way through this challenging time.
Please refer to the CDC website for the most current information about COVID-19, or to your local / state health authorities for information pertaining to your area.
On behalf of CMT Solutions, we thank all of our employees, community, laboratories, providers and patients as you continue to partner with us and trust our solutions.
We will continue to keep you updated if our conditions change and we are committed to adapting with the changes.
This was originally published on Health Affairs on October 23rd, 2019, written by Kathryn A. Phillips, Patricia A. Deverka.
Our newly released study examines the increasingly important but poorly understood role of Lab Benefit Managers (LBMs).Pharmaceutical Benefit Managers (PBMs) have generated widespread attention (often negative), but little attention has been paid to the rapid growth of LBMs. LBMs now manage genetic test benefits for hundreds of millions of enrollees and three of the four largest health plans in the U.S. use LBMs to manage genetic testing. These third party benefit managers are changing clinical and lab practice in significant ways. For example, some LBMs require prior authorization for all genetic tests, which has important implications for patients and providers, and some develop coverage policies on behalf of payers, thus changing the nature of coverage policy development in the U.S.
This is the first study to our knowledge to examine the growth and role of LBMs. We describe the LBM landscape including the major players as well as the types of services LBMs offer to providers and labs on behalf of payers. Next, we attempt to apply lessons learned from recent observations regarding PBMs to LBMs in the hopes of avoiding some of the potential negative consequences of introducing misaligned incentives among patients, clinicians, labs and insurers. While the LBM business model is distinct from PBMs, it is instructive to look more closely at the current reach of LBMs to see how the use of intermediaries might affect genetic test access, costs, and utilization over time. Finally, we outline trends to watch to develop transparent, objective evidence about the impact of LBMs on patient outcomes, and to assess trade-offs between benefits and harms from tighter utilization management practices.
This article was from the Health Affairs Blog: https://www.healthaffairs.org/do/10.1377/hblog20191021.563154/full/